Coherus Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	11.57	42.17	26.39	257.24	211.04	326.55
Revenue Growth	91.19%	59.81%	-89.74%	21.89%	-35.37%	-31.37%
Cost of Revenue	7.96	13.81	8.73	158.99	70.08	57.59
Gross Profit	3.61	28.36	17.66	98.25	140.96	268.96
Selling, General & Admin	45.89	100.6	125.48	192.02	198.48	169.71
Research & Development	101.21	108.89	91.83	109.44	199.36	363.11
Total Operating Expenses	147.1	209.49	217.32	301.45	397.84	532.82
Operating Income	-44.33	-181.13	-199.65	-203.2	-256.88	-263.86
Interest Expense	-2.33	-9	-10.73	-40.54	-32.47	-22.96
Other Non-Operating Income (Expense)	2.14	7.01	-5.01	5.47	-2.4	-0.28
Total Non-Operating Income (Expense)	-0.18	-1.99	-15.74	-35.07	-34.87	-23.24
Pretax Income	-161.15	-183.12	-215.39	-238.27	-291.75	-287.1
Provision for Income Taxes	-	-	-	-0.38	-	-
Net Income	-132.13	168.02	28.51	-237.89	-291.75	-287.1
Earnings From Discontinued Operations	29.01	351.15	243.9	-	-	-
Net Income to Common	-103.12	519.17	272.41	-237.89	-291.75	-287.1
Net Income Growth	-	90.59%	-	-	-	-
Shares Outstanding (Basic)	132	117	115	94	78	75
Shares Outstanding (Diluted)	132	117	115	94	78	75
Shares Change	14.11%	2.26%	21.65%	21.30%	2.89%	-9.63%
EPS (Basic)	-1.03	1.43	0.25	-2.53	-3.76	-3.81
EPS (Diluted)	-1.03	1.43	0.25	-2.53	-3.76	-3.81
EPS Growth	-	472.00%	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-186.03	-138.51	-20.44	-174.88	-241.12	-38.72
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-1.41	-1.18	-0.18	-1.86	-3.11	-0.51
Gross Margin	31.18%	67.24%	66.93%	38.19%	66.79%	82.36%
Operating Margin	-383.14%	-429.51%	-756.58%	-78.99%	-121.72%	-80.80%
Profit Margin	-1141.92%	398.43%	108.03%	-92.48%	-138.25%	-87.92%
FCF Margin	-1607.73%	-328.45%	-77.46%	-67.98%	-114.25%	-11.86%
EBITDA	-40.73	-177.21	-194.38	-199.41	-253.18	-260.4
EBITDA Margin	-351.98%	-420.21%	-736.58%	-77.52%	-119.97%	-79.74%
EBIT	-44.33	-181.13	-199.65	-203.2	-256.88	-263.86
EBIT Margin	-383.14%	-429.51%	-756.58%	-78.99%	-121.72%	-80.80%
Effective Tax Rate	-	0.00%	0.00%	0.16%	0.00%	0.00%

SEC Filings: 10-K · 10-Q